Surrogacy Guide

This article systematically reviews the clinical directions, affiliated hospitals, and academic backgrounds of renowned experts in the field of reproductive medicine in China, covering sub-specialties such as reproductive endocrinology, embryology, and genetic counseling. It helps patients accurately match suitable specialists based on their specific conditions—such as diminished ovarian reserve, recurrent implantation failure, and male infertility—avoiding information bias and resource misallocation during the medical consultation process.

China's ovarian reserve assessment technology primarily uses AMH serum testing, ultrasound antral follicle count (AFC), and basal FSH. AMH is not affected by the menstrual cycle and can be tested at any time, making it the most commonly used clinical indicator for ovarian reserve. Antral follicle count needs to be performed in the early menstrual phase to assess the number of available follicles in the ovaries. Evaluation criteria vary by age group, and it is recommended to complete a full set of tests at a reproductive center.

The Reproductive Center of Peking University Third Hospital (Peking University Third Hospital Reproductive Medicine Center) was established in 1984, making it one of the earliest reproductive medicine centers in China. In 1988, the team led by Professor Zhang Lizhu achieved the first successful in-vitro fertilization (IVF) birth in mainland China. This article introduces the center's founding background, development history, technological breakthroughs, and its significance for the field of assisted reproductive technology in China, covering topics such as the development of ART, IVF technology, and reproductive medicine research.

Whether and how long to lie in bed after embryo transfer is a common question for IVF patients. Based on clinical guidelines from Chinese fertility centers, this article answers post-transfer bed rest duration, proper rest methods, risks of prolonged bed rest, and activity recommendations for different situations, helping patients scientifically arrange their post-transfer life.

Current status, indications, risks, and postoperative fertility management of laparoscopic minimally invasive surgery in the field of assisted reproduction in China. A systematic evaluation of the therapeutic value of laparoscopic surgery for tubal factor infertility and endometriosis-related infertility, as well as the impact of surgical timing on subsequent assisted reproductive treatment.

China's mild stimulation ovulation induction technology uses low-dose medications to induce follicular development, suitable for people with low ovarian reserve, advanced age, or high risk of OHSS. This article analyzes the mild stimulation protocol process, applicable conditions, differences from conventional stimulation, and key clinical management points from the perspective of physician decision-making.

Sperm DNA fragmentation testing technology is widely implemented in China, primarily using SCD test and TUNEL method, to evaluate male fertility, predict assisted reproductive outcomes, and recurrent miscarriage risk. Test results need to be combined with routine semen analysis; natural pregnancy probability decreases when DFI exceeds 30%.

Answers whether Chinese assisted reproduction hospitals have WeChat official accounts, introduces functions such as appointment booking, report inquiry, and health education of reproductive center accounts, and guides patients to efficiently complete the IVF treatment process via WeChat, including follow methods, functional differences, and precautions.

China hospital qualifications can be verified online through the National Health Commission website, focusing on checking the 'Medical Institution Practice License' and human assisted reproduction technology permits. When querying, verify the institution name,诊疗科目, inspection records, and license validity period, distinguishing different technology scopes such as IVF, ICSI, PGT, to avoid choosing institutions that provide services beyond their scope.

China's Assisted Reproductive Technology Management Measures (Human Assisted Reproductive Technology Management Measures) clearly stipulate the implementation institutions, indications, ethical review, technical specifications, etc., for technologies such as IVF and artificial insemination. This article interprets the core requirements and implementation details of the management measures from a clinical perspective, helping patients understand the technical access conditions and implementation process.

Fertility preservation technology in China has entered a mature application stage, with oocyte vitrification and embryo freezing success rates comparable to international standards. This article analyzes the applicable conditions, age impact, procedural arrangements, and risk control of different technologies from the perspective of reproductive physicians' clinical decision-making, helping patients understand how to assess their own fertility preservation needs.

Chinese embryologist qualification requirements cover four dimensions: academic threshold, professional training, title evaluation, and practical skills. This article systematically reviews the certification standards, training pathways, and skill assessment indicators for reproductive center embryologists, helping practitioners and patients understand the professional thresholds and competency levels of embryologists. Content is based on domestic assisted reproductive industry standards for knowledge reference.

China's NGS whole genome sequencing technology has reached internationally advanced levels in the field of assisted reproduction, with domestic BGI MGI and imported platforms operating in parallel. It can simultaneously screen for aneuploidy, copy number variations, and single gene mutations in preimplantation genetic testing, but the choice must be made comprehensively based on testing purpose, cost, turnaround time, and professional genetic counseling capabilities.

2026 China IVF Guide: Complete process, pre-operative check-ups (AMH, FSH, semen analysis), age-specific differences, health insurance policy changes, timeline, and common misconceptions. Recommended to start preparation 3-6 months in advance for those over 35.

China's ICSI single sperm injection technology has matured, primarily addressing male factor infertility, including severe oligoasthenozoospermia, obstructive azoospermia, and previous IVF fertilization failure. This article provides a comprehensive analysis of ICSI's clinical application in assisted reproduction from the perspectives of technical principles, indications, contraindications, operational procedures, risks, and success rates, helping patients scientifically understand this technology and make informed decisions.

Clinical application, technical principles, differences from conventional ICSI, suitable populations, actual procedures, and cost factors of PIEZO-ICSI in China's assisted reproduction field. Based on the current status of domestic reproductive centers, providing objective technical evaluation and decision-making reference.

Whether a personalized ovarian stimulation protocol is reliable depends on whether it is based on a comprehensive medical evaluation. Regular fertility centers choose long protocols, antagonist protocols, or mild stimulation protocols based on indicators such as AMH, FSH, antral follicle count, age, and BMI. Fixed protocols without individualized assessment are unreliable, but scientifically formulated personalized protocols are key to improving success rates.

Hospitals in China with independent embryology labs are mainly tertiary hospital reproductive centers and some specialized hospitals approved by the National Health Commission to perform assisted reproductive technology. An independent lab refers to an in-house, self-operated embryo culture and cryopreservation facility with its own quality control system. This article outlines the criteria for identifying independent embryology labs, representative medical institutions, and how patients can verify them.

The number of successful cases at Chinese assisted reproduction hospitals varies significantly by hospital, patient age, and etiology. This article explains the definition standards for successful cases (clinical pregnancy rate/live birth rate), how to query official data, and reminds patients to be wary of exaggerated claims, providing rational evaluation methods.

PGT-M (Preimplantation Genetic Testing for Monogenic Disorders) has been maturely applied in clinical practice in China, suitable for families with monogenic diseases of known causative genes. Its technical core is precise genetic diagnosis of embryos to block the transmission of pathogenic genes. However, it must be clarified: screening accuracy is affected by factors such as detection technology and embryonic mosaicism, and it cannot cover unknown gene mutations. This article analyzes the reliability of PGT-M screening in China from three dimensions: technical principles, clinical applications, and limitations.